AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Reports Q3 revenue $5.2M, consensus $19.36M. Cash, cash equivalents and restricted cash were $667.1M as of September 30, compared to $603.0M as of ...

From designing proteins not found in nature to extending healthy lifespan, Retro Biosciences is applying AI models to advance cellular reprogramming for aging research. The company operates across ...

For French writer Laurent Binet, this seemingly innocuous (albeit tragic) accident was in fact a far more nefarious event, one that is the basis for his compelling new novel. In The 7th Function of ...